|
SKAN AG / Key word(s): Preliminary Results 22-Jan-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR SKAN announces preliminary key figures for the 2024 financial year Allschwil, 22 January 2025 – The SKAN Group AG, world market leader for high-quality isolator systems for aseptic production processes in the (bio-) pharmaceutical industry, expects based on preliminary, not yet audited figures net sales of around CHF 360 million (2023: CHF 320.0 million) and earnings before interest, taxes, depreciation and amortization (EBITDA) of around CHF 56 million (2023: CHF 50.1 million). Order intake is expected to reach around CHF 360 million (2023: CHF 295.1 million). Publication of the 2024 financial results: SKAN Group AG will publish the detailed 2024 financial results on Tuesday, March 25, 2025, at 7:00 a.m. At the same time, the 2024 Annual Report and the 2024 year-end presentation will be available for download at www.skan.com. An investor, analyst and media conference is also planned for 10:00 a.m. at the Widder Hotel in Zurich. Further details will be provided in due course. Contacts: Thomas Balmer, ir@skan.com, +41 79 703 87 28 Financial calendar:
SKAN – together always one step ahead SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organisation make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organisations) and research laboratories worldwide. Founded in 1968, SKAN today employs approximately 1400 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan, the USA and Brazil. End of Inside Information |
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Biotech Investments
Issuer: Immunic AG / Key word(s): Quarter Results 07.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc.
November 8, 2024